NextCure (NXTC)
(Delayed Data from NSDQ)
$1.60 USD
-0.03 (-1.84%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $1.64 +0.04 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
NextCure, Inc. [NXTC]
Reports for Purchase
Showing records 1 - 20 ( 63 total )
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Poster at ASCO Provides More Detail on Duration of Treatment With NC410 + Pembro
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
NC410 + Pembro Updated Data at ASCO Appear in Line With Competitor Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Phase 1b NC410 Combo Data to be Presented at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical LNCB74 Data at AACR Demonstrate Positive Efficacy and Safety Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
NC410 Combo Data Encouraging in Ovarian and MSS-CRC; 4Q23 Financials Reported
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
NC410 Development to Focus on MSS-CRC; Transitioning NC762 to LNCB74; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Catalyst-Heavy 4Q23 on the Horizon; Expectations Remain Low, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
An Unappreciated IO Company With Three Data Readouts Expected in 4Q23; Initiating at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Clinical Updates from Three Programs in 2H2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Clinical Data Updates in Second Half of 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Data Readouts from Multiple Clinical Programs in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: NextCure, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department